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Abstract
Introduction: In the context of pleiotropic vitamin D effects, its role has also been investigated in thyroid pathology, in particular autoimmune 
thyroid diseases (AITD). However, available data concerning vitamin D status in Polish patients with thyroid disorders are inconclusive. 
In the study we investigated vitamin D status and adequacy of supplementation, as well as sunlight exposure during summer months 
among adult patients with thyroid diseases. 
Material and methods: Adults with diagnosed or suspected thyroid disease were recruited almost entirely in an ambulatory setting be-
tween June and September in Northern Poland. Questionnaire examinations were performed, and serum concentrations of 25(OH)D2, 
25(OH)D3, 3-epi-25(OH)D3, and 24,25(OH)2D3 were determined by LC-MS/MS. 
Results: Thirty men and 194 women participated in the study, mean age ± standard deviation (SD): 42 ± 15 years, mean ± SD body 
mass index (BMI) 26 ± 6 kg/m2. Among the participants, 133 declared L-thyroxine treatment, 44 — Hashimoto’s thyroiditis, 40 — nodular 
goitre, and 20 — hyperthyroidism and/or Graves’ disease. 
Mean ± SD 25(OH)D level was 26.9 ± 8.2 ng/ml, and deficiency (< 20 ng/ml) was stated in 12%, insufficiency (20 ≤ 25(OH)D < 30 ng/ml) 
in 50.4% of study participants. Calcidiol was significantly higher in subjects who declared supplementation, mean ± SD: 29.4 ± 7.5 
vs. 25.2 ± 8 ng/ml. Among participants without vitamin D supplementation sunlight exposure correlated with 25(OH)D. 
The C3 epimer of 25(OH)D3 was detected in all subjects; its concentration correlated strongly with that of 25(OH)D3. 24,25(OH)2D3 levels 
also strongly correlated with those of 25(OH)D3. 
Conclusions: To our knowledge, the current study is the first in Poland to analyse vitamin D status in summer months among patients 
with thyroid diseases, as well as serum 3-epi-25(OH)D3 and 24,25(OH)2D3 concentrations. The data presented here indicate that vitamin 
D sufficiency is not attained even in summer months in patients with thyroid diseases. (Endokrynol Pol 2018; 69 (6): 653–660)
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Streszczenie
Wstęp: W badaniach nad witaminą D w kontekście jej plejotropowego działania analizowano między innymi rolę tej witaminy w roz-
woju chorób tarczycy, szczególnie tych o podłożu autoimmunologicznym (AITD). Jednak dostępne dane dotyczące stanu zaopatrzenia 
w witaminę D u polskich pacjentów z zaburzeniami tarczycy są niejednoznaczne.
W przedstawionym badaniu oceniono stan zaopatrzenia w witaminę D oraz jej suplementację, a także ekspozycję na światło słoneczne 
w miesiącach letnich u osób dorosłych z chorobami tarczycy.
Materiał i metody: Niemal wszystkie osoby dorosłe z rozpoznaną lub podejrzewaną chorobą tarczycy włączone do badania rekrutowano 
w warunkach ambulatoryjnych w okresie od czerwca do września w Północnej Polsce. Przeprowadzono badanie ankietowe oraz ozna-
czono stężenia w surowicy 25(OH)D2, 25(OH)D3, 3-epi-25(OH)D3 i 24,25(OH)2D3 za pomocą techniki LC-MS/MS. 
Wyniki: W badaniu uczestniczyło 30 mężczyzn i 194 kobiety, średnia wieku ± odchylenie standardowe (SD): 42 ± 15 lat, średnia ± SD 
wskaźnika masy ciała (BMI) 26 ± 6 kg/m2. Jak wskazują dane uzyskane w badaniu ankietowym, 133 uczestników badania przyjmowało 
L-tyroksynę, 44 miało chorobę Hashimoto, 40 — wole guzkowe, a 20 — nadczynność tarczycy i/lub chorobę Gravesa-Basedowa. 
Średnie ± SD stężenie 25(OH)D wyniosło 26,9 ± 8,2 ng/ml. Niedobór witaminy D (< 20 ng/ml) stwierdzono u 12%, a hipowitaminozę 
(20 ≤ 25(OH)D < 30 ng/ml) u 50,4% uczestników badania. Stężenie kalcydiolu było istotnie wyższe u osób, które deklarowały suplemen-
tację witaminy D, średnia ± SD: 29,4 ± 7,5 vs. 25,2 ± 8 ng/ml. W grupie uczestników, którzy nie stosowali suplementacji witaminy D, 
ekspozycja na światło słoneczne korelowała ze stężeniem 25(OH)D3. 
U wszystkich uczestników badania wykryto epimer C3 25(OH)D3, a jego stężenie silnie korelowało ze stężeniem 25(OH)D3. Stwierdzono 
również silną korelację między stężeniami 24,25(OH)2D3 i 25(OH)D3. 
Wnioski: Zgodnie z wiedzą autorów jest to pierwsze w Polsce badanie oceniające stężenie witaminy D w miesiącach letnich u osób 
z chorobami tarczycy, a także stężenia surowicze 3-epi-25(OH)D3 i 24,25(OH)2D3. Przedstawione w niniejszej pracy dane wskazują, że 
u osób z chorobami tarczycy stężenie witaminy D nawet w miesiącach letnich nie jest prawidłowe. (Endokrynol Pol 2018; 69 (6): 653–660)
Słowa kluczowe: niedobór witaminy D; kalcyfediol; światło słoneczne; promieniowanie ultrafioletowe; choroby tarczycy
Dr med. Piotr Kmieć, Department of Endocrinology and Internal Medicine, Medical University of Gdańsk, Dębinki 7, Gdańsk 80–952;  
tel: +48 58 349 28 46, fax: +48 58 349 28 41, e-mail: piotrkmiec@gumed.edu.pl
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Internal Medicine of the Medical University of Gdańsk, 
i.e. hospitalised patients. All subjects received an in-
formation sheet about the study and gave informed 
consent to participate. The only inclusion criterion 
was a diagnosed or suspected thyroid disorder (which 
included hypo- and hyperthyroidism, thyroid nodule, 
and/or cancer). There were no exclusion criteria. 
A questionnaire was used to acquire the following 
information about the participants: age, body weight, 
and height; thyroid disorder and other diseases; vita-
min D supplementation and intake of other medica-
tions; physical activity (outdoor and indoor); presence 
of muscle weakness and bone pain; skin phototype 
according to Fitzpatrick’s classification (i.e. questions 
about eye, hair, and skin colour, tanning ability); date 
of most recent tanning; attitude toward sun exposure 
(on a five-point scale ranging from “always avoid” to 
“always expose”); duration of sun exposure (“less than 
10 minutes”, “between 10 and 30 minutes”, and “more 
than 30 minutes”) per day; and parts of body (head 
and palms, arms, legs, or bathing suit) exposed to the 
sun in the preceding 14 days between 10:00 and 15:00. 
Number of days with a given duration of sunlight ex-
posure (categorised on a 1–20 scale) and body surface 
area exposed were used to calculate a sun exposure 
score (weighted arithmetic means of body surface on 
given days and points for duration of exposure). 
Venous blood drawn from study participants 
was centrifuged for 10 minutes at 3500 g, then se-
rum was transferred to separate tubes and frozen 
at –80°C. Serum tubes were transported to the 
Masdiag laboratory (Masdiag, Warsaw, Poland), 
where 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, 
24,25(OH)2D3 — inactivated vitamin D form, and 
25-hydroxy-3-epi-vitamin D3 (3-epi-25(OH)D3) were 
determined. The sample preparation method was 
based on liquid-liquid extraction of 100 µl of serum 
using hexane as an extractant, followed by DAPTAD 
derivatisation (4-(4’-dimethylaminophenyl)-1,2,4-tri-
azoline-3,5-dione). Such a solution provided the desired 
sensitivity. The analyses were performed using liquid 
chromatography coupled with tandem mass spectrom-
etry (QTRAP4500, SCIEX). Chromatographic conditions 
were optimised to achieve sufficient separation of 3-epi-
-25(OH)D3 and 25(OH)D3. The limit of detection was 
0.1 ng/ml, linear range: 0.1–10 ng/ml. The stationary 
phase was Kinetex F5 1.7 µm (50 × 2.1 mm) (Phe-
nomenex, Torrance, CA, USA). The analysis was per-
formed at a flow rate of 0.45 ml/min. The temperature 
of the column oven was 40°C. The mobile phase con-
sisted of water and acetonitrile with 0.1% formic acid 
as an additive. 
The sum of 25(OH)D2 and 25(OH)D3 is further 
referred to as 25(OH)D (calcidiol) (measuring both 
Introduction
In recent years a plethora of data has been accumulated 
that demonstrate widespread vitamin D deficiency. 
Multiple associations have also been made between 
vitamin D deficiency and deleterious health effects, 
including autoimmune, cardiovascular, and neoplastic 
diseases. The role of vitamin D has been investigated 
also in the context of autoimmune thyroid disorders 
(AITD) and to a lesser extent thyroid neoplasms [1, 2]. 
While the term “vitamin D” encompasses several 
chemical compounds, it most commonly refers to two of 
them: cholecalciferol (vitamin D3) and ergocalciferol (vi-
tamin D2), which are synthesised by animals and plants 
(and fungi), respectively. In humans cholecalciferol is the 
main form of vitamin D; synthesised from 7-dehydrocho-
lesterol (also a precursor for cholesterol) in skin exposed 
to solar ultraviolet B radiation, but also ingested in food 
products and acquired through supplementation [3]. 
Vitamin D status in humans is reflected by serum 
25-hydroxyvitamin D (25(OH)D, calcidiol) concentra-
tion. Calcidiol is formed by hydroxylation of vitamin 
D (D3 and D2) in the liver. In accordance with the 2013 
Central European guidelines, vitamin D deficiency, 
insufficiency, adequate status and high vitamin D sup-
ply was defined here by respective calcidiol concentra-
tions of: less than 20 ng/ml, 20 up to 30 ng/ml, 30 up to 
50 ng/ml, and 50 up to 100 ng/ml [4]. Calcitriol, 1,25(OH)2D, 
the fully active form of vitamin D, is acquired through 
hydroxylation of 25(OH)D by 1-alpha-hydroxylase 
(CYP27B1) in the kidneys. Furthermore, it is now well 
established that vitamin D may also be activated in 
multiple organs, which are involved in autocrine and 
paracrine regulation of local homeostasis [5].
Vitamin D deficiency has been shown to be preva-
lent in Northern Poland [6], and summer sun exposure 
was not sufficient to fully eliminate it [7, 8]. Further-
more, vitamin D deficiency was stated in up to 90% of 
Poland’s adult population [9]. The effects of vitamin D 
on the immune system have been suggested as the link 
between decreased vitamin D levels and AITD [1, 2, 10]. 
The aim of the presented study was to assess vitamin D 
status among patients with thyroid disorders in Poland 
during summer months.
Material and methods
The study was approved by the Independent Bioethics 
Commission for Research of the Medical University of 
Gdańsk, Poland.
Study participants were recruited during summer 
months (June 6 to September 13, 2017) in an ambulatory 
medical centre in Gdańsk (Endomed Medical Diagnos-
tic Centre) and at the Department of Endocrinology and 
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25-hydroxy-vitamin D forms to reflect vitamin D status 
is recommended [4]). 
Statistical analysis was performed using Graphpad 
Prism 5 (GraphPad Software). In most analyses non-para-
metric tests were used because 25(OH)D, age, and BMI 
values did not follow a Gaussian distribution (as verified 
with the Shapiro-Wilk test). Spearman rank correlations 
were calculated. The significance level was set at 0.05.
Results
Demographic characteristics
In our study 224 participants were enrolled; 30 men 
(13.4%) and 194 women. Ambulatory patients com-
prised 200 participants, while 24 persons were recruited 
in the hospital (three men). Only two hospitalised pa-
tients were admitted to our Department acutely due to 
thyroid pathology, i.e. uncontrolled hyperthyroidism, 
while others had scheduled admissions for diagnostic 
workup.
Among the enrolled study participants 198 (88%) 
were less than 65 years old. There were 58 (25.9%) over-
weight participants (i.e. with a body mass index, BMI, 
calculated by dividing the weight in kilograms by the 
square of height in meters, ≥ 25 and < 30 kg/m2) and 41 
(18.3%) obese (BMI ≥ 30 kg/m2) participants, while eight 
(3.6%) were underweight (BMI < 18.5 kg/m2) (Table I). 
Study subjects were inhabitants of the Pomerania Prov-
ince in northern Poland (with few exceptions), and 137 
lived or worked in Gdańsk. 
Thyroid disorders
Questionnaire data concerning thyroid disorders and 
their treatment are presented in Table II. Hypothyroid-
ism and/or levothyroxine treatment was stated by 62.5% 
of study participants, Hashimoto disease by 19.6%, 
nodular goitre by 17.6%, and hyperthyroidism by 7.1%. 
Among patients treated with thyroxine 78 provided the 
dose of the hormone, which ranged between 12.5 µg 
and 167.5 µg/day [median 1 µg/kg body weight, inter-
quartile range (IQR) 0.6]. 
Vitamin D metabolites and status
Table III shows basic descriptive statistics of measured 
vitamin D metabolites. Because vitamin D2 is not used 
for supplementation in Poland, the sole source of 
25(OH)D2 in this study was alimentation, which ex-
plains the low concentrations of this metabolite. 
Vitamin D deficiency (i.e. 25(OH)D concentration 
lower than 20 ng/ml) was found in 27 study partici-
pants, insufficiency in 113, and sufficiency in 76 study 
participants (Table III). The mean total calcidiol concen-
tration was 27.3 ng/ml (standard deviation, SD ± 8.1), 
median: 27.2 ng/ml (IQR, 9.1) (Table III and IV). In three 
hospital patients 25(OH)D concentration was lower 
than 10 ng/ml. 
There were no significant correlations between 
25(OH)D and BMI or age for all study subjects. Calcidiol 
concentrations were not significantly different in am-
bulatory and hospitalised patients, men and women, 
or in hyperthyroid and hypothyroid/thyroxine-treated 
subjects. 
The 3-epimer form of 25(OH)D3 was detected in 
all study participants. There was a highly significant 
Table I. Demographic characteristics of study participants
Tabela I. Charakterystyka demograficzna uczestników 
badania
Total Hospitalised
Sex Male 30 3
Female 194 21
Age 
[years]
N 224 24
Mean 42.3 46
SD (±) 14.7 16.1
Median 40 40.5
IQR 22 30.3
BMI  
[kg/m2]
N 202 24
Mean 25.9 26.1
SD (±) 5.6 7.8
Median 24.9 23.4
IQR 7.7 8.6
BMI — body mass index; IQR — interquartile range; SD — standard deviation
Table II. Questionnaire data on thyroid disorders provided 
by study participants
Tabela II. Dane na temat zaburzeń czynności tarczycy podane 
przez uczestników w badaniu ankietowym
All subjects 
n (men),  
% of total
Hospitalised 
subjects 
n (% of total)
Hashimoto’s thyroiditis 44 (1), 19.6% 6 (2.7%)
Hypothyroidism 10 (4), 4.5% 0
Treatment with L-thyroxine 
(total)
133 (10), 59.4% 10 (4.5%)
participants, who provided 
the dose
78 (3), 34,8% 10 (4.5%)
Nodular goitre 40 (9), 17.9% 2 (0.9%)
Thyroid cancer 3 (0), 1.3% 1 (0.4%)
Status post thyroid surgery 3 (0), 1.3% 0
Hyperthyroidism /  
/ Graves’ disease
20 (4), 8.9% 6 (2.7%)
Antithyroid medication 14 (4), 6.3% 5 (2.2%) 
Unknown thyroid disorder 16 (3), 7.1% 0
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strong positive correlation between concentrations of 
3-epi-25(OH)D3 and 25(OH)D3 (Fig. 1). Relative concen-
tration of 3-epi-25(OH)D3 to 25(OH)D 3 ranged between 
2.2 and 14.4% (Table IV).
Also, a highly significant strong positive correla-
tion was found between 24,25(OH)2D3 and 25(OH)D3 
(Fig. 2). The relative concentration of 25(OH)D3 to 
24,25(OH)2D3 ranged between 5.2 and 33.8, mean ± SD: 
11.1 ± 3.7, median (IQR): 10.2 (3.9). A negative correlation 
was observed between 25(OH)D3 to 24,25(OH)2D3 ratio 
and 25(OH)D3, as depicted in Figure 3. There was a weak 
negative correlation between 24,25(OH)2D3 concentra-
tion and BMI (r = –0.17, p < 0.05). 
Effects of supplementation and sun exposure 
on vitamin D status
Supplementation of vitamin D was declared by 
46.9% of participants (n = 105); their 25(OH)D concen-
trations were significantly higher than those of patients 
who did not supplement vitamin D: 28.2 vs. 25.3 ng/ml 
(IQR 9.8 and 9.4, respectively), mean ± SD: 29.4 ± 7.5 
vs. 25.2 ± 8 ng/ml (Table V). Only 31 subjects reported 
the daily cholecalciferol dose, which ranged between 
200 and 5000 IU. 
Subjects who declared vitamin D supplementation 
compared to those who did not had significantly higher 
Table III. Basic statistics of measured vitamin D metabolites
Tabela III. Podstawowe statystyki oznaczonych metabolitów witaminy D
Mean SD (±) Median Q1 Q3 Min. Max.
25(OH)D3 [ng/ml] 26.87 8.18 26.65 22.02 31.77 4.12 53.82
25(OH)D2 [ng/ml] 0.44 0.24 0.39 0.28 0.52 0.08 1.59
25(OH)D = 25(OH)D3 + 25(OH)D2 [ng/ml] 27.31 8.12 27.15 22.49 32.22 4.62 53.98
3-epi-25(OH)D3 [ng/ml] 1.63 0.89 1.41 1.05 1.95 0.24 5.66
3-epi-25(OH)D3/25(OH)D3 0.06 0.02 0.05 0.05 0.07 0.02 0.14
24,25(OH)2D3 [ng/ml] 2.81 1.37 2.54 1.86 3.66 0.28 8.57
25(OH)D3/24,25(OH)2D3 11.06 3.73 10.17 8.61 12.58 5.22 33.75
SD — standard deviation
Table IV. Vitamin D status of study participants
Tabela IV. Status witaminy D u uczestników badania
Serum 25(OH)D  
[ng/ml]
n (%)
Deficiency < 10 3 (1.3%)
10–20 24 (10.7%)
Insufficiency 20–30 113 (50.4%)
Sufficiency 30–40 62 (23.3%)
≥ 40 14 (6.3%)
Figure 1. Relationship between 3-epi-25(OH)D3 and 25(OH)
D3; Spearman r = 0.75, p < 0.0001, 95% confidence interval: 
0.69 to 0.81
Rycina 1. Zależność między stężeniami 3-epi-25(OH)D3 
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Figure 2. Relationship between 24,25(OH)2D3 and 25(OH)D3; 
Spearman r = 0.83, p < 0.0001, 95% confidence interval: 0.78 
to 0.87
Rycina 2. Zależność między stężeniami 24,25(OH)2D3 
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median 3-epi-25(OH)D3 concentrations, and median 
ratios of 25(OH)D3 to 24,25(OH)2D3 (Table V). 
Data for calculating sun exposure scores were avail-
able for 174 study participants of the study; among 
these subjects:
 — significantly different median 25(OH)D concentra-
tions were found between those who did and did 
not supplement vitamin D: 28.2 (IQR = 8.6, n = 77) 
versus 25.4 ng/ml (IQR = 7.9, n = 97), respectively 
(Mann Whitney test, p < 0.005); 
 — significant Spearman rank correlations were found 
between 25(OH)D concentrations and skin photo-
type, r = 0.18 (p < 0.05), date of most recent tan-
ning, r = 0.17 (p < 0.05), and attitude toward sun 
exposure, r = 0.17 (p < 0.05). 
Among 77 participants of the study who declared vi-
tamin D supplementation and whose sun exposure data 
were provided, no significant differences in 25(OH)D 
concentration were found between sexes, and no 
correlations were found between 25(OH)D level and 
BMI, skin phototype, date of tanning, attitude toward 
sunlight exposure, and sun exposure score. 
There were 97 study subjects who provided in-
formation for calculating sun exposure scores and 
reported no vitamin D supplementation. Among 
these subjects calcidiol concentrations significantly 
correlated with:
 — sun exposure score, r = 0.24, p < 0.05;
 — skin phototype, r = 0.25, p < 0.05;
 — date of most recent tanning, r = 0.26, p < 0.05;
 — attitude toward sun exposure, r = 0.31, p < 0.005 
(Spearman rank test) (Fig. 4). 
For 127 study participants we were able to pro-
vide TSH concentrations, and for 97 free thyroxine 
concentrations, which were measured either during 
hospitalisation in our Department or in ambulatory 
setting preceding a doctor ’s appointment due to thy-
roid disease. Study participants were categorised as 
hypothyroid based on TSH level above 3.5 mIU/ml (11 
patients), hyperthyroid based on TSH < 0.1 mIU/ml 
(15 patients), and euthyroid (101 patients). Hypothy-
roid patients had significantly lower 25(OH)D and 
3epi-25(OH)D3 levels than euthyroid subjects (Table 
VI). There were no significant differences in BMI, 
age, sun exposure parameters, and supplementation 
Table V. Vitamin D status and supplementation
Tabela V. Status witaminy D a suplementacja
Cholecalciferol supplementation
No Yes
25(OH)D [ng/ml]
n 115 105
Mean 25.2 29.4 (*) 
SD 8 7.5
Median 25.3 28.2 (*)
Q1 20.6 24.1
Q3 30 33.9
Min. 4.6 10.8
Max. 53 51.3
3-epi-25(OH)D3 [ng/ml]
Median (IQR) 1.25 (0.88) 1.65 (0.99) (*)
25(OH)D3 to 24,25(OH)2D3 ratio
Median (IQR) 9.8 (3.7) 10.9 (5) (*)
IQR — interquartile range; SD — standard deviation; 25(OH)D: p = 0.0003 in 
Mann-Whitney test, p = 0.0001 in t test, 3-epi-25(OH)D3: p = 0.001, 25(OH)D3 
to 24,25(OH)2D3 ratio: p = 0.028
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Figure 3. Relationship between 25(OH)D3/24,25(OH)2D3 ratio 
and 25(OH)D3; Spearman r = –0.46, p < 0.0001, 95% confidence 
interval: –0.56 to –0.34
Rycina 3. Zależność między stosunkiem stężeń 25(OH)D3/
/ 24,25(OH)2D3 a stężeniem 25(OH)D3
Always
40
0
20
60
Never Rarely Sometimes Usually
 2
5
(O
H
)D
 [
n
g
/m
l]
Figure 4. Vitamin D and declared attitude toward sun exposure 
in subjects without vitamin D supplementation; lines and bars 
denote medians and interquartile ranges; n = 97
Rycina 4. Status witaminy D a deklarowana ekspozycja na słońce 
u osób stosujących suplementację witaminy D
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between hypo-, eu-, and hyperthyroid patients. There 
were no statistically significant correlations between 
TSH (as well as free thyroxine) and vitamin D metabo-
lites, age, or BMI. 
Discussion and conclusions
Vitamin D status of participants recruited in this study 
corresponds well with findings by other authors in 
Poland. Bartoszewicz et al. recorded a mean calcidiol 
level of 25.5 ng/ml in the April–September period in 
57 healthy pregnant women, 42 of whom supplemented 
vitamin D [11]. Krzywański et al. reported mean sum-
mer 25(OH)D levels in 409 elite Polish outdoor and 
indoor athletes of 36 and 27 ng/ml, respectively [12]. In 
our previous study, mean 25(OH)D among 304 adult 
volunteers (59% female, mean age 46 years) in autumn 
was 21.1 ng/ml, and less than 20% of participants de-
clared vitamin D supplementation [7]. 
In the current study, the C3 epimer form of 25(OH)D3 
was also measured. Vitamin D metabolism via the C3 
epimerisation pathway has been discovered recently, 
but its significance has not been investigated sufficiently 
[13]. It has been observed that all major vitamin D 
metabolites can be epimerised and later metabolised 
analogously to standard ones; however, the C3 epimer 
form of active vitamin D (C3-epi-1,25(OH)2D) does not 
exhibit all effects of the classic isomer [13]. In the current 
study, in only 13 participants (5.8%) vitamin D status 
would change, if concentrations of 3-epi-25(OH)D3 
were taken into account (i.e. if vitamin D status was 
reflected by the sum of 25(OH)D2, 25(OH)D3, as well as 
3-epi-25(OH)D3). This result is comparable to reports by 
other authors; also, as previously reported, 25(OH)D3 
Table VI. Vitamin D status and thyroid function
Tabela VI. Status witaminy D a czynność tarczycy
Hypothyroid Euthyroid Hyperthyroid
TSH [mIU/]
n 11 101 15
Mean (SD) 8.26 (12.43) 1.52 (0.73) 0.0009 (0.012)
Median (IQR) 4.6 (1.78) 1.49 (0.98) 0.005 (0.017)
Range 3.55–45.65 0.11–3.16 0–0.034
fT4 [pmol/l]
n 8 74 15
Mean (SD) 14.2 (3.91) 16.07 (2.66) 24.15 (16.38)
Median (IQR) 13.2 (6.9) 15.93 (4.47) 17.2 (21.25)
Range 9.03–20.4 10.6–21.7 9.17–61.2
25(OH)D [ng/ml]
n 11 101 15
Mean (SD) 21.38 (7.5) 27.91 (7.85)* 24.34 (9.5)
Median (IQR) 22.56 (10.68) 27.69 (10.13)# 25.41 (15.59)
Range 5.82–30.10 9.85–51.26 4.62–41.78
25(OH)D3/24,25(OH)2D3
n 11 101 15
Mean (SD) 11.82 (3.61) 11.31 (4.04) 11.31 (3.48)
Median (IQR) 11.09 (3.73) 10.53 (4.83) 11.03 (5.72)
Range 7.18–20.79 5.23–33.75 7.33–18.89
3-epi-25(OH)D3 [ng/ml]
n 11 101 15
Mean (SD) 1.03 (0.39) 1.7 (0.94)* 1.3 (0.6)
Median (IQR) 1.12 (0.71) 1.46 (0.91)# 1.11 (1.02)
Range 0.24–1.49 0.43–5.45 0.42–2.34
IQR — interquartile range; SD — standard deviation; 25(OH)D and 3-epi-25(OH)D3 concentrations were significantly different between hypothyroid versus euthyroid 
patients, respectively: ANOVA with Tukey’s post hoc test: p = 0.0179 and p = 0.0223, respectively, Kruskall-Walis test p = 0.0309 and p = 0.0133, respectively
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and 3-epi-25(OH)D3 concentrations correlated posi-
tively [14, 15].
Similarly to previous studies, a strong positive cor-
relation between calcidiol and 24,25(OH)2D3 was dem-
onstrated here [16, 17]. Increased conversion to inactive 
vitamin D form in persons with higher vitamin D levels 
was reported previously [18]. The ratio of 25(OH)D3 to 
24,25(OH)2D3 (or its reciprocal) has been proposed as 
an indicator of 24-hydroxylase deficiency and response 
to vitamin D supplementation [19]. Loss-of-function 
mutations in CYP24A1, the gene that encodes 24-hy-
droxylase, result in a range of clinical disorders, among 
them idiopathic infantile hypercalcaemia (IIH) and 
adult-onset nephrocalcinosis and nephrolithiasis [20]. 
Because serum 24(OH)D3 is low not only in 24-hydroxy-
lase deficiency but also in vitamin D deficiency, the ratio 
of calcidiol to its catabolite may indicate enzymatic 
deficiency: normal range of the ratio rarely exceeds 20, 
whereas in IIH it is greater than 80 [19]. In respect to 
assessing response to vitamin D supplementation us-
ing the 25(OH)D3 to 24,25(OH)2D3 ratio, its basal lower 
values correlated with lesser increment in calcidiol after 
treatment [16, 21]. 
In our study almost half of the participants (47%) 
declared vitamin D supplementation. It may be specu-
lated that participants using highest doses (5000 IU/day, 
n = 5) were treated for vitamin D deficiency, while 
the remainder merely supplemented to prevent it. In 
spite of supplementation or treatment and collection 
of samples during summer, still more than 50% of the 
study participants did not reach vitamin D sufficiency. 
Assuming patient compliance, our data point to the 
need for testing 25(OH)D levels to achieve target con-
centrations. In Poland, at 51°45’N latitude, Sewerynek 
et al. recently investigated (among others) the effect 
of two doses of cholecalciferol on vitamin D status 
in healthy women aged 20–30 years over a period of 
three months between January and May (total n = 106, 
only 67 adhered to therapy). Interestingly, 1500 IU of 
cholecalciferol increased mean 25(OH)D from 12.6 to 
29.4 ng/ml (baseline deficiency group), while 800 IU 
increased mean 25(OH)D from 25.2 to 36.9 ng/ml (group 
with baseline 25(OH)D > 20 ng/ml) [22]. These results 
hint at the effect of vitamin D synthesis due to sunlight 
apart from supplementation. 
The questionnaire examination in this study yielded 
data that indicate the effect of natural UVB exposure on 
vitamin D status. Interestingly, among participants who 
supplemented cholecalciferol, there were no statistically 
significant correlations in investigated parameters related 
to sunlight. Other authors found that self-reported 
sun exposure correlates with calcidiol levels [23, 24]. In 
a recent study, Vignali et al. developed an algorithm 
assessing vitamin D status, which used simple pieces of 
information: age, BMI, duration of daily sunlight expo-
sure of the face, hands, and legs, attitude toward going 
outdoors (“often”/”sometimes”/”seldom”), and participa-
tion in a beach holiday in the past year. Their study was 
performed at 40°50’N latitude in August and March; 620 
participants were recruited; vitamin D supplementation 
was an exclusion criterion. Vitamin D status in one of four 
concentration ranges (< 10, 10–20, 20–30, > 30 ng/ml) 
was predicted correctly in over 90% of participants [25]. 
A similar tool might be developed for predicting vitamin 
D status for other latitudes; it would probably require the 
consideration of air pollution, among others. 
Research data concerning associations between 
autoimmune thyroid disease (and thyroid cancer) are 
inconclusive [2]. In our study 25(OH)D levels were not 
measured longitudinally; therefore, it is difficult to draw 
conclusions about the association between vitamin D 
status and thyroid disorders, although hypothyroid 
study participants had lower calcidiol levels than eu-
thyroid. In a recent study, Mirhosseini et al. reported 
a significant decrease in thyroid stimulating hormone 
(TSH) concentrations (indicating reduction in overt and 
subclinical hypothyroidism), anti-thyroid peroxidase, 
and anti-thyroglobulin titres after a one year follow-up 
among approximately 11.000 Canadians who took part 
in a program aimed at reaching 25(OH)D levels of at 
least 40 ng/ml. This target was attained by over 72% of 
participants and mean vitamin D dose was approxi-
mately 4000 IU/day [26]. Other studies, including small 
patient samples in Poland, also indicate associations 
between AITD and vitamin D status [27, 28]. 
The present study has a number of limitations. Most 
importantly, thyroid function measures were not avail-
able for all participants, clinical data were acquired by 
questionnaire and in many instances missing informa-
tion concerned doses of vitamin D supplements, and 
co-morbidities were poorly reported (i.e. ones that ac-
companied thyroid disease); in the study convenience 
sampling was applied; also, the methodology of the 
questionnaire examination related to sun exposure 
was simplistic (fortnight recall and not diary data).
In conclusion, to our knowledge, in the current 
study, for the first time in Poland, vitamin D status was 
examined among patients with thyroid diseases during 
summer. Furthermore, we report simultaneous analysis 
of four vitamin D derivatives including 3-epi-25(OH)D
3 
and 24,25(OH)2D3 concentrations. Vitamin D sufficiency 
was recorded in fewer than 30% of the examined study 
participants, despite cholecalciferol supplementation in 
almost half of the subjects. Bearing in mind the associa-
tions between vitamin D status and thyroid disorders, in 
particular AITD, treatment and supplementation doses 
of vitamin D should be verified by testing 25(OH)D to 
reach recommended vitamin D status. 
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